Xenomics Names Research Oncologist and Biotechnology Executive Dr. David Sidransky to Board of Directors
Xenomics, Inc. announced that it has named David Sidransky, M.D., of Johns Hopkins University to its Board of Directors.
Dr. Sidransky currently serves as Director of the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University and is Professor of Oncology, Urology, Cellular & Molecular Medicine, Pathology, Otolaryngology and Genetics at Johns Hopkins University School of Medicine. Dr. Sidransky is certified in Internal Medicine and Medical Oncology by the American Board of Medicine.
He is a founder of several private biotechnology companies and has served on the scientific advisory boards of many noted private and public companies, including Medimmune, Roche, and Amgen. He is formerly a member of the Recombinant DNA Advisory Committee at the National Institute of Health and is currently the Vice Chairman of the Board of ImClone Systems.
Other news from the department people
